• James O. Woolliscroft


Generalize Anxiety Disorder Personality Disorder Main Side Effect Pressure Ulcer Main Drug Interaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Key references

  1. 1.
    Zerby AL III, Lee MJ, Brugge WR, Mueller PR: Endoscopic sonography of the upper gastrointestinal tract and pancreas. AJR Am J Roentgenol 1996, 166: 45–50.CrossRefGoogle Scholar
  2. 2.
    Raptopoulos V, Steer ML, Sheiman RG, et al: The use of helical CT and CT angiography to predict vascular involvement from pancreatic cancer: correlation with findings at surgery. AJR Am J Roentgencol 1997, 168: 971–977.CrossRefGoogle Scholar
  3. 3.
    Gattani AM, Mandeli J, Bruckner HW: Tumor markers in patients with pancreatic carcinoma. Cancer 1996, 78: 57–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Lehman GA, Uzer M: Pancreatic cancer. Curr Pract Med 1998, 4: 870–875.Google Scholar
  5. 5.
    van Riel JMGH, van Groeningen CJ, Pinedo HM, Giaccone G: Current chemotherapeutic possibilities in pancreaticobiliary cancer. Ann Oncol 1999, 10 (Suppl4): S157–S161.CrossRefGoogle Scholar
  6. 6.
    Burns HA, Moore Mi, Andersen L, etal: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15: 2403–2413.Google Scholar
  7. 7.
    Howden ON, Woods BL: Self-expanding metal stents for palliative treatment of malignant biliary and duodenal stenoses. Gastromtest Endosc 1995, 42: 104–105.Google Scholar
  8. 1.
    Bradley EL III: A clinically based classification system for acute pancreatitis. Arch Surg 1993, 128: 586–590.PubMedCrossRefGoogle Scholar
  9. 2.
    Brugge WR: Acute and chronic pancreatitis. Curr Pract Med 1998, 1: 861–867.Google Scholar
  10. 3.
    Poston GJ, Williamson RCN: Surgical management of acute pancreatitis. Br J Surg 1990, 77: 5–12.PubMedCrossRefGoogle Scholar
  11. 4.
    Fernandez del Castillo C, Rattner DW, Warshaw AL: Acute pancreatitis. Lancet 1993, 342: 475–479.CrossRefGoogle Scholar
  12. 5.
    Steinberg WM, et al: Controversies in clinical pancreatology. Pancreas 1996, 13: 219–225.CrossRefGoogle Scholar
  13. 1.
    Steer ML, et al.: Chronic pancreatitis. N Engl J Med 1995, 332: 1482–1490.PubMedCrossRefGoogle Scholar
  14. 2.
    Brugge WR: Acute and chronic pancreatitis, Curr PractMed 1998, 1: 861–867.Google Scholar
  15. 3.
    Ihse I, Permerth J: Enzyme therapy and pancreatic pain. Acta ChirScand 1990, 156: 281–283.PubMedGoogle Scholar
  16. 4.
    Ammann RW, et al: Course of alcoholic chronic pancreatitis. Gastroenterology 1996, 111: 224–231.PubMedCrossRefGoogle Scholar
  17. 5.
    Malfertheiner P, Dominquez-Munoz JE, Büchler M: Diagnosis and staging of chronic pancreatitis. In Standards in Pancreatic Surgery. Edited by Beger HG, etal. Berlin: Springer-Verlag; 1993: 297–313.CrossRefGoogle Scholar
  18. 6.
    Nealon WH, Thompson JC Progressive loss of pancreatic function in chronic pancreatitis is delayed by main pancreatic duct decompression. Ann Surg 1993, 217: 458–466.PubMedCrossRefGoogle Scholar
  19. 7.
    Watanapa P, Williams RC: Pancreatic sphincterotomy and sphincteroplasty. Gut 1992, 33: 865–867.PubMedCrossRefGoogle Scholar
  20. 8.
    Beger HG, Büchler M, Bittner R: The duodenum preserving resection of the head of the pancreas (DPRHP) in patients with chronic pancreatitis and an inflammatory mass in the head. Acta Chir Scand 1990, 156: 309–315.PubMedGoogle Scholar
  21. 1.
    Nesse RM, Bamurski MA: Anxiety disorders in primary care. In: Primary Care Psychiatry. Edited by Knespe DJ, Robi MB, Schwenk TL. Philadelphia: W.B. Saunders, 1997.Google Scholar
  22. 2.
    Boyer W: Serotonin uptake inhibitors are superior to imiprimine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995, 10: 45–49.PubMedCrossRefGoogle Scholar
  23. 3.
    Folles DG, Fuller WC: Anxiety disorders and insomnia in geriatric patients. Pychiatric Clin North Am 1997, 29 (1): 137–164.Google Scholar
  24. 1.
    Calne DB: Treatment of Parkinson’s disease. N Erigi J Med 1993, 329: 1021–1027.CrossRefGoogle Scholar
  25. 2.
    Marsden CD: Parkinson’s disease. J Neurol Neurosurg Psychiatry 1994, 57: 672–681.PubMedCrossRefGoogle Scholar
  26. 1.
    Anonymous: ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.Google Scholar
  27. 2.
    Bronisch T, et al: The Munich diagnostic checklist for the assessment of DSM-III-R personality disorders for use in routine clinical care and research. Eur Arch Psychiatry Clin Neurosd 1992, 242: 77–81.CrossRefGoogle Scholar
  28. 3.
    Stein G: Drug treatment of personality disorders. Br J Psychiatry 1992, 166: 67–84.Google Scholar
  29. 4.
    Speckens AM, et al.: Cognitive behavioural therapy for medically unexplained physical symptoms: a randomised controlled trail. BMJ 1995, 311: 1328–1332.PubMedCrossRefGoogle Scholar
  30. Mclsaac WJ, Gael V, Slaughter PM, etal: Reconsidering sore throats: problems with current clinical practice. Can Fain Physician 1997, 43: 485–493.Google Scholar
  31. 2.
    Carroll K, Reimer L: Microbiology and laboratory diagnosis of upper respiratory infections. Clin Infect Dis 1996, 23: 442–448.PubMedCrossRefGoogle Scholar
  32. 3.
    Kline JA, Runge JW: Streptococcal pharyngitis: a review of pathophysiology, diagnosis, and management. J Emerg Med 1994, 12: 665–680.PubMedCrossRefGoogle Scholar
  33. 4.
    Blumer JL, Goldfarb J: Meta-analysis in the evaluation of treatment for streptococcal pharyngitis: a review. Clin Ther 1994, 16: 604–620.PubMedGoogle Scholar
  34. 1.
    George JN, Shattil SJ: The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991, 324: 27–38.PubMedCrossRefGoogle Scholar
  35. 2.
    George JN, Raskob GE: Idiopathic thrombocytopenic purpura: a concise summary of the pathophysiology and diagnosis in children and adults. Semin Hematol 1998, 35 (Suppl 1): 5–8.PubMedGoogle Scholar
  36. 3.
    Tarantino MD, Goldsmith G: Treatment of acute immune thrombocytopenic purpura. Semin Hematol 1998, 35 (Suppl 1): 28–35.PubMedGoogle Scholar
  37. 4.
    Blanchette V, Freedman J, Garvey B: Management of chronic immune thrombocytopenic purpura in children and adults. Semin Hematol 1998, 35 (Suppl 1): 36–51.PubMedGoogle Scholar
  38. 5.
    Bolan CD, Alving BM: Pharmacologic agents in the management of bleeding disorders. Transfusion 1990, 30: 541–551.PubMedCrossRefGoogle Scholar
  39. 6.
    Kwaan HC, Soff GA: Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997, 34: 159–166.PubMedGoogle Scholar
  40. 1.
    Collins TR, Sahn SA: Thoracentesis: complications, patient experience and diagnostic value. Chest 1987, 91: 817–819.PubMedCrossRefGoogle Scholar
  41. 2.
    Bone R: The techniques of diagnostic and therapeutic thoracentesis. J Crit Illness 1990, 5: 371–379.Google Scholar
  42. 3.
    Light R, et al.: Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972, 77: 507–513.PubMedGoogle Scholar
  43. 4.
    Keller SM: Current and future therapy for malignant pleural effusion. Chest 1993, 103 (suppi): 635–675.CrossRefGoogle Scholar
  44. 5.
    Sahn S: Pleural effusion in lung cancer. Clin Chest Med 1993, 14: 189–200.PubMedGoogle Scholar
  45. 6.
    Light RW, Vargas FS: Pleural sclerosis for the treatment of pneumothorax and pleural effusion. Lung 1997, 175: 213–223.PubMedCrossRefGoogle Scholar
  46. 1.
    Fine M, Smith D, Singer D: Hospitalization decision in patients with community- acquired pneumonia: a prospective study. Am J Med 1990, 89: 713–721.PubMedCrossRefGoogle Scholar
  47. 2.
    Fang G, etal New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine 1990, 69:307–316.Google Scholar
  48. 3.
    Bartlett JG, Mundy LM: Community- acquired pneumonia. N Engl J Med 1995, 333: 1618–1624.PubMedCrossRefGoogle Scholar
  49. 4.
    Bartlett JG, Breiman RF Mandell LA, File TM Jr: Comrftunity-acquired pneumonia in adults: guidelines for management. Guidelines from the Infectious Disease Society of America. Clin Infect Dis 1998, 26: 811–838.PubMedCrossRefGoogle Scholar
  50. 5.
    Niederman MS, et al: American Thoracic Society guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993, 148: 1418–1426.PubMedCrossRefGoogle Scholar
  51. 6.
    Fine MJ, Smith MA, Carson CA, et al: Prognosis and outcome of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996, 275: 134–141.PubMedCrossRefGoogle Scholar
  52. 7.
    The choice of antibacterial drugs. Med Lett Drugs Ther 1999, 41 (1064): 95–104.Google Scholar
  53. 1.
    Fox R, et al: Oestrogen and androgen states in oligo-amenorrhoeic women with polycystic ovaries. Br J Obstet Gynaecol 1991, 98: 294–299.PubMedCrossRefGoogle Scholar
  54. 2.
    Fox R, et al: Polycystic ovarian disease: diagnostic methods. Contemp Rev Obstet Gynaecol 1992, 4: 84–89.Google Scholar
  55. 3.
    Frank S: Polycystic ovary syndrome. N Engl J Med 1995, 333: 853–861.CrossRefGoogle Scholar
  56. 4.
    Conway GS, et al.: Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome, Clin Endocrinol 1992, 37: 119–125.CrossRefGoogle Scholar
  57. 5.
    Jacobs HS: Polycystic ovary syndrome: aetiology and management. Curr Opm Obstet Gynecol 1995, 7: 203–208.CrossRefGoogle Scholar
  58. 1.
    Lestico MR, et al.: Polymyalgia rheumatica. Clin Pharmacol 1993, 12: 571–580.Google Scholar
  59. 2.
    Chmelewsk» WL, et al: Presenting features and outcomes in patients undergoing temporal artery biopsy: a review of 98 patients. Arch Intern Med 1992, 152: 1690–1695.CrossRefGoogle Scholar
  60. 3.
    Reech KA, et al: Neurologic manifestations of giant cell arteritis. Am J Med 1990, 89: 67–72.CrossRefGoogle Scholar
  61. 4.
    Kyle Vf Cawston TE, Hazleman BL: Erythrocyte sedimentation rate and c reactive protein in the assessment of polymyalgia rheumatical giant cell arteritis on presentation and during follow-up. Ann Rheum Dis 1989, 48: 667–671.PubMedCrossRefGoogle Scholar
  62. 5.
    Wilke WS, Hoffman GS: Treatment of corticosteroid resistant giant cell arteritis. Rheum Dis Clin North Am 1995, 21: 59–71.PubMedGoogle Scholar
  63. 6.
    Kyle V, Hazleman BL Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 1989, 48: 658–661.PubMedCrossRefGoogle Scholar
  64. 7.
    Krall PL, Mazanec Di, Wilke WS: Methotrexate for corticosteroid-resistant polymyalgia rheumatica and giant-cell arteritis. Cleve Clin J Med 1989, 56: 253–277.PubMedGoogle Scholar
  65. 8.
    Kyle V, Hazleman BL: Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989, 48: 662 - 666.PubMedCrossRefGoogle Scholar
  66. 9.
    Behn AR, Perera T, Myles AB: Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983, 42: 374–378.PubMedCrossRefGoogle Scholar
  67. 10.
    Hunder GG: Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 1997, 81: 195–219.PubMedCrossRefGoogle Scholar
  68. 1.
    Susman JL: Postpartum depressive disorders. J Fam Pract 1996, 43 (supp l): S17–S24.PubMedGoogle Scholar
  69. 2.
    O’Hara MW: Social support, life events and depression during pregnancy and the peurperium. Arch Gen Psych 1986, 43: 569–573.CrossRefGoogle Scholar
  70. 3.
    Cooper Pi, etal.: Fortnightly review: postnatal depression. BMJ 1998, 316: 1884–1886.PubMedCrossRefGoogle Scholar
  71. 1.
    Brawer MK: Prostate-specific antigen: current status. CA Cancer J Clin 1999, 49: 264–281.PubMedCrossRefGoogle Scholar
  72. 2.
    Hahnfeld LE, Moon TD: Prostate cancer. Med Clin North Am 1999, 83: 1231–1245.PubMedCrossRefGoogle Scholar
  73. 3.
    Gamick MB, Fair WR: Prostate cancer: emerging concepts (part 1). Ann Intern Med 1996, 125: 118–125.Google Scholar
  74. 4.
    Gamick MB, Fair WR: Prostate cancer: emerging concepts (part 2). Ann Intern Med 1996, 125: 205–212.Google Scholar
  75. 5.
    Henry RY, O’Mahony D: Treatment of prostate cancer. J Clin Pharm Ther 1999, 24: 93–102.PubMedCrossRefGoogle Scholar
  76. 1.
    Sacher RA: Thrombophilia: a genetic predisposition to thrombosis. Trans Am Clin Climatol Assoc 1999, 110: 51–61.PubMedGoogle Scholar
  77. 2.
    Hirsch J, Weitz JL: New antithrombotic agents. Lancet 1999, 353: 1431–1436.CrossRefGoogle Scholar
  78. 3.
    Lowe GDO: Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992, 305: 567–574.CrossRefGoogle Scholar
  79. 4.
    Raschke RA, Reilly BM, Guidry JR, et al: The weight-based heparin dosing nomogram compared with a “standard care” nomogram. Ann Intern Med 1993, 119: 874–881.PubMedGoogle Scholar
  80. 5.
    The Columbus Investigators: Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997, 337: 657–662.CrossRefGoogle Scholar
  81. 6.
    Poller L: Oral anticoagulation. J Clin Pathol 1990, 43: 177–183.CrossRefGoogle Scholar
  82. 1.
    Bridges NA, Brook CDG; Premature sexual development. In Clinical Endocrinology. Edited by Grossman A. Oxford: Blackwell Scientific Publications; 1992: 837–846.Google Scholar
  83. 2.
    Stanhope R, Albanese A, Shalet S: Delayed puberty. BMJ 1992, 305: 790.PubMedCrossRefGoogle Scholar

General references

  1. Brown KE, Young NS: Parvovirus B19 in human disease. Am Rev Med 1997, 48: 59–67.CrossRefGoogle Scholar
  2. Gay Ni, etal: Age specific antibody prevalence to parvovirus B19: how many women are infected in pregnancy? Comm Dis Rep 1994, 4:R104–R107,Google Scholar
  3. Levy R, Waissman A, Blomberg G, Hagay I: Infection by parvovirus B19 during pregnancy: a review. Obstet Gynecol Surv 1997, 52: 254–259.PubMedCrossRefGoogle Scholar
  4. Pattison JR: Human parvovirus B19. BMJ 1994, 308: 149–150.PubMedCrossRefGoogle Scholar
  5. Clifford CP, Davies GJ: Tuberculous pericarditis with rapid progression to constriction. BMJ 1993, 307: 1052–1054.PubMedCrossRefGoogle Scholar
  6. Sagrista-Sauleda J, et al: Long-term follow-up of idiopathic pericardial effusion. N Engl J Med 1999, 341: 2054–2059.PubMedCrossRefGoogle Scholar
  7. Ziskind AA, et al: Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: description of technique and report of the first 50 cases. J Am Coll Cardiol 1993, 21: 1–5.PubMedCrossRefGoogle Scholar
  8. Armstrong JH, Barcia PJ: Pilonidal sinus disease: the conservative approach. Arch Surg 1994, 129: 914–918.PubMedCrossRefGoogle Scholar
  9. Barnett JL: Anorectal disease. In Textbook of Gastroenterology, edn 3. Edited by Yamada T. Philadelphia: Lippincott Williams & Wilkins; 1999: 2083–2106.Google Scholar
  10. Sebastian MW: Pilonidal cysts and sinuses. In Textbook of Surgery, edn 15. Edited by Sabiston DC, Jr. Philadelphia: WB Saunders; 1996: 1330–1334.Google Scholar
  11. Masur H: Prevention and treatment of Pneumocystis pneumonia. N Engl J Med 1992, 327: 1853–1860.PubMedCrossRefGoogle Scholar
  12. Moe AA, Hardy WD: Pneumocystis carinii infection in the HIV-seropositive patient. Infect Dis Clin North Am 1994, 8: 331–364.PubMedGoogle Scholar
  13. Murray JF: Pulmonary complications of HIV infection. Am Rev Med 1996, 47: 117–126.CrossRefGoogle Scholar
  14. Santamauro JT, Stover DE: Pneumocystis carinii pneumonia. Med Clin North Am 81: 299–318.Google Scholar
  15. Aurfíen D, et al.: The postpolio syndrome-a critical comment to the diagnosis. Acta Neurol Scand 1999, 100: 76–80.CrossRefGoogle Scholar
  16. Kid D, et al.: Late functional deterioration following paralytic poliomyelitis. QJM 1997, 90: 189–196.CrossRefGoogle Scholar
  17. Spector SA, et al: Strength gains without muscle injury after strength training in patients with postpolio muscular atrophy. Muscle Nerve 1996, 19: 1282–1290.PubMedCrossRefGoogle Scholar
  18. Thorsteinsson G: Management of postpolio syndrome. Mayo Clin Proc 1997, 72: 627–638.PubMedGoogle Scholar
  19. Trojan DA, et al.: A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. Neurology 1999, 53: 1225–1233.PubMedCrossRefGoogle Scholar
  20. The post-polio syndrome: advances in the pathogenesis and treatment. Conference proceedings, ßethesda, Maryland, April 27–30, 1994. Ann NY Acad Sci 1995, 753:1–412.Google Scholar
  21. Pressure Ulcers in Adults: Prediction and Prevention. Rockville: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services; 1992 [AHCPR Publication 92-0047.] (Available at U.S. National Library of Medicine’s Health Services; Technology Assessment Text (HSTAT) web page: Pressure Ulcers in Adults: Treatment Rockville: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services; 1994. [AHCPR Publication 94-0075.]Google Scholar
  22. Osterling J, Fuks Z, Lee CT, Scher HI: Cancer of the prostate. In Cancer: Principles and Practice of Oncology, edn 5. Edited by De Vita VT Jr, Hellman S, Rosenberg SA. Philadelphia: Lippincott-Raven; 1997: 1322–1386.Google Scholar
  23. Thomas DP, Roberts HR: Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997, 126: 638–644.PubMedGoogle Scholar
  24. Denman ST: A review of pruritus. J Am Acad Dermatol 1986, 14: 375–392.PubMedCrossRefGoogle Scholar
  25. Giichrest B: Pruritus: pathogenesis, therapy, and significance in systemic disease states. Arch Intern Med 1982, 142: 101–105.CrossRefGoogle Scholar
  26. Greaves MW, Wall PD: Pathophysiology of itching. Lancet 1996, 348: 938–940.PubMedCrossRefGoogle Scholar
  27. Kam PCA, Tan KH: Pruritus—itching for a cause and relief? Anaesthesia 1996, 51: 1133–1138.PubMedCrossRefGoogle Scholar
  28. Millikan LE: Treating pruritus: what’s new in safe relief of symptoms. Postgrad Med 1996, 99: 173–184.PubMedGoogle Scholar
  29. Yosipovitch G, David M: The diagnostic and therapeutic approach to idiopathic generalized pruritus. Int J Dermatol 1999, 38: 881–887.PubMedCrossRefGoogle Scholar
  30. Farber EM, Nail ML: The natural history of psoriasis in 5600 patients. Dermatologica 1974, 148: 1–18.PubMedCrossRefGoogle Scholar
  31. Greaves MW, Weinstein GD: Treatment of psoriasis. N Engl J Med 1995, 332: 581–588.PubMedCrossRefGoogle Scholar
  32. Highton A, Quell J: Calcipotreine ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotreine study group. J Am Acad Dermatol 1995, 32: 67–72.PubMedCrossRefGoogle Scholar
  33. Koo J: Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999, 41 (3 Pt 2): S25–S28.PubMedCrossRefGoogle Scholar
  34. Nickoloff BJ: The immunologic and genetic basis of psoriasis. Arch Dermatol 1999, 135: 1104–1110.PubMedCrossRefGoogle Scholar
  35. Saurat JH: Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 1999, 41 (3 Pt 2): S2–S26.PubMedCrossRefGoogle Scholar
  36. Weinstein GD: Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Br J Dermatol 1996, 135 (suppl 49): 32–36.PubMedCrossRefGoogle Scholar
  37. Zelickson BD, Muller SA: Generalized pustular psoriasis: a review of 63 cases. Arch Dermatol 1991, 127: 1339–1345.PubMedCrossRefGoogle Scholar
  38. Dichter JR, Levine SJF, Shelhamer JH: Approach to the immunocompromised host with pulmonary symptoms. Hematol Oncol Clin North Am 1993, 7: 887–912.PubMedGoogle Scholar
  39. Lartholory O, Dupont B: Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev 1997, 10: 477–504.Google Scholar
  40. Verra F, etai: Bronchoalveolar lavage in immunocompromised patients: clinical and functional consequences. Chest 1992, 101: 1215–1220.PubMedCrossRefGoogle Scholar
  41. Wade JC: Treatment of fungal and other opportunistic infections in immuno–compromised patients. Leukemia 1997, 11 (suppl 4): 5538–S539.Google Scholar
  42. Carson JL, Kelley MA, Duff A, et al: The clinical course of pulmonary embolism. N Engl J Med 1992, 326: 1240–1245.PubMedCrossRefGoogle Scholar
  43. Goldhaber SZ: Pulmonary embolism. N Engl J Med 1998, 339: 93–104.PubMedCrossRefGoogle Scholar
  44. Abenhaim L, Moride Y, Brenot F, et al.: Appetite-suppressant drugs and the risk of primary pulmonary hypertension: International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 335: 609–616.PubMedCrossRefGoogle Scholar
  45. D’Alonzo GE, Barst RJ, Ayres SM, et al: Survival in patients with primary pulmonary hypertension: results from a National Prospective Registry. Ann Intern Med 1991, 115: 343.PubMedGoogle Scholar
  46. Rubin LJ: Primary pulmonary hypertension. N Engl J Med 1997, 336: 111–117.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • James O. Woolliscroft
    • 1
    • 2
  1. 1.University of Michigan Medical SchoolAnn ArborUSA
  2. 2.University of Michigan HospitalsAnn ArborUSA

Personalised recommendations